Sign In
Buy CELZ
$0.88
+0.0190 (+2.21%)
At Close: Jul 17, 2026
Creative Medical Technology Holdings Issues Mid-Year Update
09:00am, Wednesday, 01'st Jul 2026
Highlights Significant Clinical, Regulatory, and Strategic Progress, Supported by a Disciplined Capital Allocation Strategy Highlights Significant Clinical, Regulatory, and Strategic Progress, Support
Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.5 Million Gross Proceeds
02:07pm, Tuesday, 30'th Jun 2026
PHOENIX, June 30, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc., (Nasdaq: CELZ) (the “Company”), a biotechnology company dedicated to the advancement of regenerative therapeu
PHOENIX, June 22, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) ("Creative Medical" or the "Company"), a clinical-stage biotechnology company advancing regenerativ
Creative Medical Technology opens nationwide burn-pit data registry
03:52pm, Tuesday, 16'th Jun 2026
Creative Medical Technology Holdings Inc (NASDAQ:CELZ) has moved Project PHOENIX into a nationwide virtual data-collection phase, opening enrollment for a regulatory-approved registry that the compa
Creative Medical Technology opens nationwide burn-pit data registry
11:49am, Tuesday, 16'th Jun 2026
Creative Medical Technology Holdings Inc (NASDAQ:CELZ) has moved Project PHOENIX into a nationwide virtual data-collection phase, opening enrollment for a...
The regulatory approved CELZ-Biodefense platform is designed to scale to at least 1,000 veterans through AI-enabled mobile-app data collection and field-capable logistics
Ultrasome™ Demonstrates Strong Clinical Signal While Leveraging GMP-Produced CELZ-201 (Olastrocel) to Target Large, Underserved Osteoarthritis Market
Data Show Strong Functional and Pain Improvements Supported by Excellent Safety Profile Data Show Strong Functional and Pain Improvements Supported by Excellent Safety Profile
Creative Medical Technology Holdings Receives Regulatory Approval for BioDefense Burn Pit Initiative
09:15am, Tuesday, 06'th Jan 2026
PHOENIX, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”), a clinical-stage biotechnology company advancing reg
Completion of Enrollment Positions CELZ for Near-Term Data Catalysts and Accelerates Path Toward Commercialization of a Transformative, Non-Opioid Therapy for Chronic Lower Back Pain Completion of Enr
Global assignment of this unique name enhances international clarity, strengthens regulatory positioning, and supports olastrocel's advancement across large unmet-need global markets Global assignment
Bears are Losing Control Over Creative Medical Technology Holdings, Inc. (CELZ), Here's Why It's a 'Buy' Now
10:55am, Wednesday, 05'th Nov 2025
Creative Medical Technology Holdings, Inc. (CELZ) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings
Creative Medical Technology Holdings, Inc. Ignites Next-Gen Regenerative BioDefense Initiative for U.S. Veterans Exposed to Burn Pits
09:15am, Thursday, 30'th Oct 2025
Selects Greenstone Biosciences to Accelerate AI-Driven iPSC Precision Medicine Platform Selects Greenstone Biosciences to Accelerate AI-Driven iPSC Precision Medicine Platform
Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.2 Million Gross Proceeds
09:00am, Wednesday, 29'th Oct 2025
PHOENIX, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc., (Nasdaq: CELZ) (the “Company”), a clinical-stage biotechnology company pioneering regenerative immunotherapy,
Creative Medical Technology Holdings Issues Letter to Shareholders
08:15am, Monday, 27'th Oct 2025
Ongoing Phase II Clinical Trials, Recently Issued Patents, and AI Integration Initiatives Set the Stage for Continuing Progress in 2026 Ongoing Phase II Clinical Trials, Recently Issued Patents, and
